comprehensive -WSS

comprehensive

author：fashion 2025-08-28 13:06:01 - browse：32

Under the Affordable Care Act, health insurers are required to cover all costs associated with preventive care — including PrEP, or pre-exposure prophylactic treatment for HIV. But now all preventive care coverage is under threat, thanks to a lawsuit filed by employers who believe they shouldn’t be required to pay for care that violates their religious beliefs.

While coverage for PrEP access is largely unchanged as the court case makes its way through the legal system, Richard Hughes IV, a partner with the law firm Epstein Becker Green, says that protecting the status quo isn’t enough. For instance, currently you have to jump through extra hoops to get long-acting injectable PrEP covered by insurance.

But Hughes has a better idea for how to not only protect but also expand access to PrEP.

On this episode of the “First Opinion Podcast,” I spoke to Hughes about his proposal, why access to PrEP has never been what it should be, the Supreme Court’s current approach to health care, and more.

“If a provider has a bad experience with a previous patient experiencing non-coverage, they might say to the next patient, ‘Well, I’m not sure this is going to be covered.’ And that can be really discouraging,” Hughes said. “What we really need to create that clarity for patients is for this law to be upheld, for the recommendations to be clear, and for providers to have the assurance that they will be covered by payers.”

Our conversation was based on his recent First Opinion op-ed, “How to protect PrEP coverage, no matter what happens in Braidwood v. Becerra.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — First Opinion authors to feature on the podcast, kudos, or darts — email us at [email protected] and please put “podcast” in the subject line.

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Readout Newsletter: Merck, J&J, and long Covid

explore

WSS

FDA's Woodcock to retire early next year

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

In key trial, Verve's treatment lowers cholesterol levels in patients

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Readout LOUD podcast: A CRISPR milestone, biotech mixology

knowledge

comprehensive

hotspot

After affirmative action ruling, medical educators look to 'holistic review'

Copay coupons to count toward deductibles, after Biden court move

How to save PrEP access — and even expand it

Gain of function research would be limited under House proposal

Alkermes shareholders re

Morphosys mixed study results for blood cancer drug

Continuity nursing helped my family in our darkest PICU moments

Independent physicians launch a new lobbying group

Bright Health sells Medicare Advantage business to Molina

eGenesis tests gene

hotspot

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Why doctors need education on FDA device approval process

NIH director takes cautious approach to Biden drug pricing priority

Readout Newsletter: Merck, J&J, and long Covid

EU regulator recommends expanding Mounjaro approval to obesity

explore

focus

explore

leisure time